There is increasing evidence for the use of psychotherapies, HRB Open Research clinicians when determining treatment course and will inform future research into psychotherapies for chronic pain.
Introduction including cognitive behavioural therapy, acceptance and commitment therapy, and mindfulness based stress reduction therapy, as an approach to management of chronic pain. Similarly, online psychotherapeutic interventions have been shown to be efficacious, and to arguably overcome practical barriers associated with traditional face-to-face treatment for chronic pain. This is a protocol for a systematic review and network meta-analysis aiming to evaluate and rank psychotherapies (delivered in person and online) for chronic pain patients.
Four databases, namely the Cochrane Central Register Methods/ design: of Controlled Trials (CENTRAL), MEDLINE, EMBASE and PsycINFO will be searched from inception. Randomised controlled trials that have evaluated psychological interventions for pain management delivered online or in person will be included in the review. Data will be independently extracted in duplicate and the Cochrane Collaboration Risk of Bias Tool will be used to assess study quality. Measures of pain interference will be extracted as the primary outcome and measures of psychological distress will be extracted as the secondary outcome. A network meta-analysis will generate indirect comparisons of psychotherapies across treatment trials. Rankings of psychotherapies for chronic pain will be made available.
A variety of psychotherapies, delivered both online and in Discussion: person, have been used in an attempt to help manage chronic pain. Although occasional head to head trials have been conducted, little evidence exists to help identify which psychotherapy is most effective in reducing pain interference. The current review will address this gap in the literature and compare the psychotherapies used for internet delivered and in person interventions for chronic pain in relation to the reduction of pain interference and psychological distress. Results will provide a guide for clinicians when determining treatment course and will inform future 1 1 1,2 1 1 1 1 1
Introduction

Chronic pain
Chronic pain refers to pain ("an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage" [IASP, 2012; Merskey et al., 1979] ) that persists for more than three months. Chronic pain is highly prevalent, and one of the leading causes of long-term disability and reduced quality of life globally ( )), these online interventions for chronic pain have been shown to be efficacious and have potential for use in a health care system.
Why is it important to do this review?
Psychotherapies are generally accepted as a treatment option for chronic pain patients. CBT has historically been considered the gold standard treatment, however, with research into different psychotherapies yielding positive results, it is difficult to know the most appropriate direction in either a clinical or research setting. There has also been an increase in internet delivered interventions for chronic pain, however, there is a dearth of research evaluating the efficacy of online psychotherapies in comparison to their counterparts delivered in person.
The current review will investigate these comparisons using a network-meta analysis (NMA). This will facilitate comparisons regarding the relative efficacy of different psychotherapies and delivery modalities. In the context of a systematic review, NMA is a statistical technique enabling comparisons of multiple treatments through direct and indirect comparisons across trials that use a common comparator (for further discussion, see Jansen et al., 2014; Naci et al., 2013).
Objective
The objective of this review is to compare the effectiveness of relevant online and in-person psychotherapeutic interventions for chronic pain management.
Methods
Protocol and registration
This systematic review and NMA will be conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the PRISMA Network Meta-Analysis extension statement (see Reporting guidelines; Hutton et al., 2015; Moher et al., 2009). In accordance with these recommendations, this review will use PICO to frame and report review criteria; as such, participants, interventions, comparisons, outcome(s) and study design of included studies will be reported. The protocol for this study was registered with the International Prospective Register of Systematic Reviews (PROSPERO) database (registration number: CRD42016048518) on 1 November 2016.
Types of studies
Only randomised controlled trials (RCTs) comparing a psychological intervention, with at least one of an alternative psychological intervention, waitlist control (WLC), treatment-as-usual (TAU) or non-psychological intervention (for example, exercise, education and medical therapy) will be eligible for inclusion. Eligible psychological interventions must have identifiable psychotherapeutic content such as behavioural (for example, biofeedback, relaxation or behaviour monitoring) or cognitive behavioural (for example, coping skills, cognitive re-constructing or problem solving) components. The interventions must be delivered in person or via the internet.
There are no restrictions placed on treatment intensity, duration or number of psychotherapeutic techniques employed. Studies must be full-text journal articles available in English, published in peer-reviewed journals, and available using database access or through contacting study authors.
Types of participants
Eligible participants must be adults (>18 years) Types of outcome measures Primary outcomes. Studies will only be included in the NMA if they contain a self-reported measure of pain related interference or similar, for example pain related disability or impact.
Secondary outcomes.
A second network will be created to investigate the secondary outcome which will include selfreported scales of psychological distress (including depression, anxiety, negative affect or psychological stress).
Electronic searches
The following databases will be searched from inception: EMBASE, MEDLINE, CENTRAL (Cochrane Library), and PsycINFO. Searches strategies will be the same for all databases; however necessary changes will be made to account for differences in interfaces. The search strategy is described in Table 1 (see extended data (O'Connor, 2019)).
Searching other resources
Reference lists of relevant systematic reviews will be searched to identify additional relevant studies. The metaRegister of Controlled Trials (mRCT), clinicaltrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) will also be searched. This review will only include studies published in peer-reviewed journals; dissertations, unpublished papers and on-going studies will be excluded.
Study selection
Studies will be managed in Endnote X7. The research team will screen titles and abstracts to identify duplicate studies and then screen for any studies that do not satisfy the inclusion criteria. 10% of studies will be screened in duplicate to ensure consistency. Studies not available in English will be excluded at this time. Two authors (SQ and CJ) will independently screen full papers of the remaining studies for inclusion in agreement with the inclusion criteria. Studies will be sequentially excluded via the exclusion categories if they do not satisfy the criteria. Disagreements between screeners will be discussed, and where a decision cannot be reached, a third reviewer (SH) will mediate. A flow chart will graphically depict the exclusion of studies.
Data collection process
Data will be extracted in duplicate into a pre-prepared data extraction Excel sheet, to be piloted with three studies and amended if necessary before data extraction begins proper. Authors of included papers will be contacted if it is necessary to recover missing data.
Data items
Data will be extracted in accordance with the following categories:
• Participants: sample size, percentage female, mean age, diagnosis, mean years of pain. • The type of psychotherapy/control employed in each arm.
• Primary measure used to record each outcome.
• Means and standard deviations at post intervention of suitable outcome measures and the measure used to collect the data.
Geometry of the network A network diagram will visually represent available evidence, depicting the possible comparisons of any two psychotherapies (for example, CBT vs ACT) and the comparison of delivery methods of psychotherapy (for example, CBT vs iCBT). Any arms not directly connected to the network will not be included in analysis.
Risk of bias in included Studies
As participants and intervention providers are unable to be blinded in studies assessing psychological interventions, the bias domain assessing blinding of participants/personnel will be omitted from this review. Similarly, as this review focuses solely on self-report measures, the bias domain assessing blinding of outcome assessors will also be omitted. Risk of bias will be assessed by two independent reviewers. Using the Cochrane Collaboration Risk of Bias, studies will be classified as being of low, high or an unclear risk of bias based on the following six domains; random sequence generation, allocation concealment, incomplete outcome data, selective reporting bias, use of intention-to-treat analysis, uneven distribution of potential cofounders at baseline. For more detail see Slattery et al. (2017) .
Quality of evidence
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria will be used to judge the quality of evidence for direct, indirect and NMA effect estimates yielded within the network (Puhan et al., 2014). The quality of the effect estimates will be judged based on the methodological limitations of the included trials, imprecision, indirectness, inconsistency, and publication bias. Each comparison will be considered to be of high, moderate, low, or very low quality based on these criteria.
Summary measures
This review will use Stata 13 for all analyses. Mean differences between groups and 95% confidence intervals will be reported. Where outcomes are obtained using a variety of measures, standardised mean differences (SMD) will be calculated and reported with their 95% confidence intervals. To adjust for the SMD direction, the mean score of measures in which higher scores are indicative of lower levels of the desired construct (for example, higher scores on the SF-36 indicate lower levels of disability) will be subtracted from the maximum value of that measure (Higgins & Green, 2008). If no standard deviations are reported, they will be calculated from standard errors or confidence intervals that are available. Where suitable data are unavailable, study authors will be contacted in an attempt to retrieve data.
Planned methods of analysis
This review will generate comparisons of psychotherapies delivered online and in person with a view to determining which psychotherapy most effectively reduces pain interference and psychological distress respectively in a chronic pain population. Pair-wise meta-analyses) . Where data are available, pairwise meta-analyses (using Stata 13) of each comparison will act as an exploratory analysis. In the event that significant heterogeneity is discovered, a random effects model will be used. Forest plots will be used to illustrate the individual and pooled effect sizes.
Exploratory analysis (
Network meta-analysis. An NMA random effects model based on the SMD will be generated in Stata 13. The model will take a frequentist approach, calculating the probability that the observed data would have occurred under their sampling distribution for hypothesised values of the parameters. A network forest plot and interval plot will be created to graphically represent the effect size of each included study. Treatment rankings and SUCRA cumulative ranking probabilities will be created to identify the most effective psychotherapies.
This form of analysis has both risks and benefits. As single intervention RCTs become more popular (Eccleston et al., 2014) , and head to head trials are atypical, it is important to be able to generate such comparisons. The increasing use of network meta-analysis within psychological research, and in particular in eHealth research, will impact research synthesis, allowing new inferences to be drawn. NMA allows interventions never directly compared in a single trial to be compared, and generates comparisons between all included psychotherapies (regardless of delivery method). However, while promising, the use of NMA has also been considered somewhat controversial (Salanti, 2012) . Assumptions underlying the model, issues with inconsistency and the observational nature of indirect comparisons all fuel misgiving. However, when appropriately and conservatively used to synthesise research and aid decision making, they are extremely beneficial and influential.
Classification of arms.
For the primary analysis, studies will be grouped based on the type of psychotherapy employed and the modality of delivery (for example, in person vs. online CBT). Each category must have data from more than one study to warrant inclusion in the network. Otherwise, such studies will be categorised as "other" and further subcategorised based on the delivery modality. For studies employing combinations of psychotherapeutic techniques that do not coincide with a specific intervention format, such trials will be grouped in a "multimodal" category which will be further subcategorized based on the delivery modality. As low statistical power between comparisons is typically a concern when conducting NMAs (Thorlund & Millis, 2012) and large numbers of interventions employing unconventional and unique psychotherapeutic formats are anticipated, the purpose of this categorisation procedure is to avoid low statistical power between trial comparisons. Studies utilising a medium of psychotherapy delivery that does not meet our inclusion criteria (such as over the phone or teleconferencing) will be categorised as "other delivery modalities", providing that at least one arm in that study employs an eligible delivery modality. Trial arms including WLC or TAU will be categorised as inactive controls whereas arms assessing interventions without identifiable psychological components (for example, exercise, education and medical therapy) will be categorised as active controls.
Assessment of inconsistency Statistical heterogeneity and inconsistency
This review will pool studies according to the psychotherapy used and its delivery method. Given the variety in study length, engagement required, and samples used, notable heterogeneity is anticipated. During exploratory analyses, statistical heterogeneity will be assessed using the I 2 statistic, which calculates the percentage of variability due to heterogeneity and not chance.
In accordance with the Cochrane Handbook, an I 2 value of less than 40% is non-significant, a value of between 30% and 60% represents moderate heterogeneity, a value of between 50% and 90% represents substantial heterogeneity and an I 2 value of between 75% and 100% represents considerable heterogeneity. Within the NMA, overall consistency will be assessed using the inconsistency model provided in Stata 13 and a local test will be conducted to investigate loop inconsistency.
Risk of bias across studies
As part of the exploratory analysis, funnel plots of both outcomes will be generated in Stata 13. These plots will be assessed for symmetry to determine the presence of publication bias. The Egger Test will also be conducted using Stata 13, to investigate whether study size is related to the study estimate.
Additional analyses
The influence of studies at a high risk of bias will be investigated by removing them from exploratory pair wise meta-analysis one at a time. If it is observed that they have had undue influence over the synthesised effect estimate (i.e., there is a significant change in the estimate), they will be removed from further analysis.
Dissemination of information
We intend on disseminating the findings through traditional academic platforms including peer-reviewed journals and academic conferences. We will also disseminate the findings through the Centre for Pain Research's public facing channels (such as our website and social media). In doing so, we hope to facilitate the dissemination of our findings to all stakeholders including clinicians, researchers, and chronic pain patients.
Study status
We have finished the search and study screening phases and are currently preparing to extract data from the included studies. Following data extraction, studies will be categorised based on the treatment type and delivery modality. Following study categorization, the analyses, quality of evidence assessment, and write up will be conducted.
Discussion
Contribution to literature It is generally accepted that psychotherapies are effective in assisting pain management for a chronic pain population. Furthermore, there has been an increase in the number and variety of psychotherapies delivered online for chronic pain. Although research has been done in this area (Tang, 2018; Vugts et al., 2018), to date, in the context of chronic pain, there is no clear indication as to which psychotherapy delivered either in person or online is the most effective. The proposed review will address this gap in the literature.
This review will extend previous research in the area by quantitatively comparing a variety of psychotherapies delivered both online and in person to identify the most efficacious in the context of chronic pain. Specifically, the NMA will return rankings, determining which psychotherapy and modality has been the most effective in reducing the primary outcome, pain interference. Such information will guide clinicians, as they choose psychotherapies to use when delivering an intervention for chronic pain.
As the treatment rankings yielded by the NMA will indicate the relative efficacy and cost-effectiveness of different psychological treatments for chronic pain management, the rankings will enable treatment providers to select the most suitable treatment options for their patients. For example, if a particular intervention is found to be very effective but expensive to implement, it would be important for clinicians to know the following most effective treatment, while keeping the cost-effectiveness of each intervention into consideration. In much the same way the rankings will be an aid to researchers choosing components for chronic pain studies. Additionally, through implementing the GRADE criteria, this review will provide an indication of the methodological quality of the available research in psychotherapy for chronic pain management, and the extent to which the methodological quality could have influenced the findings.
Limitations A significant degree of heterogeneity is anticipated due to trials being grouped regardless of variations in intervention format or sample characteristics. This could lead to high uncertainty surrounding the effect estimates and consequently bias any inferences (Riley et al., 2017) . Additionally, as studies will be grouped regardless of chronic pain-type, the generalizability of the findings towards specific diagnoses will be compromised. As all studies employing multiple psychotherapeutic techniques will be categorized as "multimodal" and all studies employing unconventional psychotherapeutic strategies will be categorised as "other", this could result in further heterogeneity between the included trials. Additionally, deciphering the effective components of such categories will be impossible using this categorisation procedure. Although research examining the impact of language restrictions within meta-analyses is mixed (Jüni et al., 2002; Wang et al., 2015) , this inclusion criterion introduces the possibility of language bias into the review. As only follow-up data will be synthesised, the findings will provide no insight into the long-term sustainability of the treatments. As recipients of psychological interventions are unable to be blinded to their treatment condition, all of the studies incorporated in this review are susceptible to detection and allegiance biases (Munder et al., 2011) . Additionally, as this review focuses solely on self-report measures, all included studies are susceptible to response bias or social desirability (Rosenman et al., 2011) . These inherent biases could consequently inflate the treatments' effects (Shean, 2014). 1.
Implications of the review
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Although the authors will search the clinical trial registers, they only include studies published in peer-review journals. They should consider the possibility of publication bias.
The authors plan to exclude any interventions that don't directly connected to the network. However, this is a systematic review and NMA, they should include such interventions and, in addition to the NMA, summarize results.
The words used should remain consistent throughout the paper. For example, the authors use "quality" to describe the risk of bias of individual RCT in abstract, but "risk of bias" is used in method section. They should stick to risk of bias for individual studies, and restrict quality to the overall body of evidence.
The description on benefit and risk of NMA is not about the methods; they should delete or move to discussion section.
If SD is still unavailable after attempting to all methods mentioned, what do the authors plan to do? Do they plan to use another SD imputation method?
Global test of inconsistency should be calculated.
Sensitivity analysis excluding studies with high risk of bias will be planned only for pairwise meta-analysis, but it also should be performed for NMA. In addition, how do the authors classify individual studies into high and low risk of bias?
There are now two Cochrane risk of bias instruments for RCTs. The authors propose to use the older one. It has advantages over the newer one but it has an important disadvantage: the unclear risk of bias categorization is problematic. It turns out that people can make reasonable inferences regarding risk of bias when it is unclear (see Akl The paragraphs about evidence for the efficacy of (online) psychotherapy largely focusses on statistical significance of previous studies. Maybe, a more nuanced description can be given, also mentioning the effect sizes and methodological quality of previous research and its implications: how about potential risks of bias assessed in previous reviews, and clinical relevance of psychotherapies for chronic pain (in general)?
Another potential area for improvement is the specific rationale for conducting a NMA: The statement "There has also been an increase in internet delivered interventions for chronic pain, however, there is a dearth of research evaluating the efficacy of online psychotherapies in comparison to their counterparts delivered in person. The current review will investigate these comparisons using a meta-analysis (NMA)" could also be read as a plea for more primary research on direct comparisons of psychotherapies via internet or in-person.
The objective has been formulated in terms of a method, comparing treatments is a means and not an end in itself. I suggest to formulate the objective in terms of a theoretical problem: what exactly does one want to learn? Thus, the research question is not explicitly stated. The aim, as stated in the abstract ('evaluate and rank psychotherapies') is very ambitious. To this end, better primary evaluation studies might be needed more. Bluntly said, there is still a considerable risk of 'garbage in, garbage out'. Nonetheless, I agree that this NMA can provide complementary insights to the literature. Suggestions are:
Explain a bit more about variation through 'intervention format or sample characteristics'. For example, patients with depression are sometimes included and sometimes not, the recruitment base can be 'open' (from the general public via internet) or 'closed' (from clinics or work settings), patients with particularly high education levels and computer self-efficacy to self-select for internet-delivered formats. Fidelity of implementation (not only attrition) can be an influence. Is it possible to take account of some moderating factors in the NMA? Will there be enough information per type of psychotherapy to do so?
Formulate clearer (theory-based) research questions and hypotheses (can you specify the "hypothesized values of the parameters"?). Since there is so much uncertainty about the processes by which psychotherapies are effective, I consider it to be legitimate to use NMA more as an exploratorative tool.
More details could be added with respect to: -Inclusion and exclusion criteria: I suggest that you be more precise: Report clear criteria or exhaustive lists instead of examples of "psychotherapeutic content" and "debilitating diseases". This leaves questions like: is expressive writing instruction psychotherapeutic content? Is arthritis a debilitating disease?
The choice of another study to exclude patients with headache is not an actual argument to do the same. Maybe, add a paragraph with specific a priori classifications of how, and on what basis, different kinds of psychotherapy are based on approaches, techniques, and delivery modes. Are there any criteria with regard to the methods that studies have used to screen the patients? -Which systematic reviews will be searched to identify additional relevant studies?
Describe how you will deal with risk of bias and small sample sizes of included studies in the NMA.
